| Literature DB >> 35216421 |
Garrett Jones1, Tae Jin Lee1, Joshua Glass1, Grace Rountree1, Lane Ulrich2, Amy Estes2, Mary Sezer2, Wenbo Zhi1, Shruti Sharma1,2, Ashok Sharma1,2,3.
Abstract
The tear film is a multi-layer fluid that covers the corneal and conjunctival epithelia of the eye and provides lubrication, nutrients, and protection from the outside environment. Tear fluid contains a high concentration of proteins and has thus been recognized as a potential source of biomarkers for ocular disorders due to its proximity to disease sites on the ocular surface and the non-invasive nature of its collection. This is particularly true in the case of dry eye disease, which directly impacts the tear film and its components. Proteomic analysis of tear fluid is challenging mainly due to the wide dynamic range of proteins and the small sample volumes. However, recent advancements in mass spectrometry have revolutionized the field of proteomics enabling unprecedented depth, speed, and accuracy, even with small sample volumes. In this study using the Orbitrap Fusion Tribrid mass spectrometer, we compared four different mass spectrometry workflows for the proteomic analysis of tear fluid collected via Schirmer strips. We were able to establish a method of in-strip protein digestion that identified >3000 proteins in human tear samples from 11 healthy subjects. Our method offers a significant improvement in the number of proteins identified compared to previously reported methods without pooling samples.Entities:
Keywords: biomarkers; dry eye disease; mass spectrometry; ocular surface; proteomics; tear film
Mesh:
Substances:
Year: 2022 PMID: 35216421 PMCID: PMC8875482 DOI: 10.3390/ijms23042307
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Comparison of two extraction methods (Method A and B) and two fragmentation methods (CID and HCD) for tear fluid processing. Tear fluid was collected using Schirmer strips (n = 11), and each strip was cut longitudinally into two equal parts. In Method A, proteins were first extracted, and Schirmer strips were removed by filter-aided centrifugation prior to digestion. In Method B, Schirmer strips were cut into 5 mm pieces, and in-strip protein digestion was performed. Digested products from each method then underwent LC–MS/MS analysis using both collision-induced dissociation (CID) and higher-energy collisional dissociation (HCD) fragmentation techniques. The average number of unique proteins () identified per sample using each workflow is displayed.
Demographic characteristics of healthy subjects included in this study.
| Sample ID | Age | Sex | Race |
|---|---|---|---|
| S1 | 27 | F | White |
| S2 | 50 | F | Other |
| S3 | 30 | F | Other |
| S4 | 22 | M | White |
| S5 | 40 | M | Other |
| S6 | 27 | F | White |
| S7 | 21 | F | White |
| S8 | 45 | M | Other |
| S9 | 25 | F | White |
| S10 | 26 | F | White |
| S11 | 22 | F | White |
Figure 2In-strip protein digestion (Method B) provides a significant increase in both protein and peptide yield compared to post-extraction protein digestion (Method A) in tear fluid samples. The average protein and peptide counts per sample identified in all four workflows were compared via two-way ANOVA with Tukey’s correction. (A) Method B identified more proteins than Method A when paired with both CID and HCD fragmentation. (B) In-strip protein digestion also identified more peptides than post-extraction digestion following both CID and HCD fragmentation. Results are expressed as means ± SD; n = 11/group; * p-value <0.05.
Figure 3Distribution of mean protein expression by sample proportion in the four different workflows. Peptide–spectrum matches (PSMs) from the 11 tear samples were log2 transformed for each digestion and fragmentation method performed to compare differences in mean protein expression between workflows. Further, proteins detected in the 11 samples were proportionally assessed and subdivided into four categories based on trends of detection for each method: High (shown in black; detected in >75% of samples), Medium (shown in green; detected in 50–75%), Low (shown in red; detected in 25–50%), and Rare (shown in blue; detected in 5–25%).
Total number of unique proteins identified in tear samples using four different workflows.
| Number of Unique Proteins Identified | Method A | Method B | ||
|---|---|---|---|---|
| CID | HCD | CID | HCD | |
| High (detected in >75% of samples) | 122 | 112 | 178 | 182 |
| Medium (detected in 50–75% of samples) | 92 | 90 | 153 | 147 |
| Low (detected in 25–50% of samples) | 248 | 258 | 366 | 373 |
| Rare (detected in 5–25% of samples) | 2237 | 2310 | 2596 | 2668 |
| Total | 2699 | 2770 | 3293 | 3370 |
Top 50 proteins identified in tear samples using in-strip protein digestion and HCD fragmentation.
| S. No. | UniProt | Gene Symbol | Description | Mean PSM |
|---|---|---|---|---|
| 1 | P02788 |
| Lactotransferrin | 2802.91 |
| 2 | P31025 |
| Lipocalin-1 | 1300.64 |
| 3 | P02768 |
| Albumin | 874.18 |
| 4 | P12273 |
| Prolactin-inducible protein | 572.46 |
| 5 | P01876 |
| Immunoglobulin heavy constant alpha 1 | 386.19 |
| 6 | P61626 |
| Lysozyme C | 380.45 |
| 7 | P01833 |
| Polymeric immunoglobulin receptor | 275.36 |
| 8 | Q9GZZ8 |
| Extracellular glycoprotein lacritin | 263.91 |
| 9 | P01834 |
| Immunoglobulin kappa constant | 230.09 |
| 10 | P0DOX2 |
| Immunoglobulin alpha-2 heavy chain | 212.87 |
| 11 | P25311 |
| Zinc-alpha-2-glycoprotein | 203.00 |
| 12 | P0DOX7 |
| Immunoglobulin kappa light chain | 189.36 |
| 13 | P01036 |
| Cystatin-S | 185.90 |
| 14 | O75556 |
| Mammaglobin-B | 137.72 |
| 15 | Q16378 |
| Proline-rich protein 4 | 130.54 |
| 16 | P01037 |
| Cystatin-SN | 115.40 |
| 17 | P19013 |
| Keratin, type II cytoskeletal 4 | 100.11 |
| 18 | Q99935 |
| Opiorphin prepropeptide | 97.72 |
| 19 | P60709 |
| Actin, cytoplasmic 1 | 97.63 |
| 20 | P06733 |
| Alpha-enolase | 96.63 |
| 21 | P04083 |
| Annexin A1 | 95.45 |
| 22 | Q9UGM3 |
| Deleted in malignant brain tumors 1 protein | 86.00 |
| 23 | P01024 |
| Complement C3 | 80.54 |
| 24 | P02787 |
| Serotransferrin | 78.72 |
| 25 | B9A064 |
| Immunoglobulin lambda-like polypeptide 5 | 76.11 |
| 26 | Q8N3C0 |
| Activating signal cointegrator 1 complex subunit 3 | 73.45 |
| 27 | P0DOX5 |
| Immunoglobulin gamma-1 heavy chain | 73.00 |
| 28 | P0DOY2 |
| Immunoglobulin lambda constant 2 | 70.18 |
| 29 | P13646 |
| Keratin, type I cytoskeletal 13 | 70.11 |
| 30 | P08727 |
| Keratin, type I cytoskeletal 19 | 66.00 |
| 31 | P13647 |
| Keratin, type II cytoskeletal 5 | 56.00 |
| 32 | P09211 |
| Glutathione S-transferase P | 51.18 |
| 33 | P68032 |
| Actin, alpha cardiac muscle 1 | 48.10 |
| 34 | P09228 |
| Cystatin-SA | 47.71 |
| 35 | P01860 |
| Immunoglobulin heavy constant gamma 3 | 47.14 |
| 36 | P14618 |
| Pyruvate kinase PKM | 46.54 |
| 37 | P01591 |
| Immunoglobulin J chain | 46.00 |
| 38 | P98160 |
| Heparan sulfate proteoglycan core protein | 45.72 |
| 39 | P07355 |
| Annexin A2 | 44.81 |
| 40 | P0DOX6 |
| Immunoglobulin mu heavy chain | 44.28 |
| 41 | P21980 |
| Protein-glutamine gamma-glutamyltransferase 2 | 43.00 |
| 42 | P01871 |
| Immunoglobulin heavy constant mu | 41.90 |
| 43 | P30740 |
| Leukocyte elastase inhibitor | 40.54 |
| 44 | P98088 |
| Mucin-5AC | 40.33 |
| 45 | P02538 |
| Keratin, type II cytoskeletal 6A | 40.33 |
| 46 | P00450 |
| Ceruloplasmin | 40.18 |
| 47 | P00352 |
| Aldehyde dehydrogenase 1A1 | 40.18 |
| 48 | P01861 |
| Immunoglobulin heavy constant gamma 4 | 40.00 |
| 49 | P01859 |
| Immunoglobulin heavy constant gamma 2 | 37.90 |
| 50 | P08729 |
| Keratin, type II cytoskeletal 7 | 37.14 |
Major protein families identified in human tear samples.
| Families | Group | Count | Proteins | |||||
|---|---|---|---|---|---|---|---|---|
| Immunoglobulin | High |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
| ||||
| Medium | 8 |
|
|
|
|
|
| |
|
|
| |||||||
| Low | 7 |
|
|
|
|
|
| |
|
| ||||||||
| Rare | 29 |
|
|
|
|
|
| |
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
| |||||
| Keratin | High | 7 |
|
|
|
|
|
|
|
| ||||||||
| Medium | 5 |
|
|
|
|
| ||
| Low | 2 |
|
| |||||
| Rare | 12 |
|
|
|
|
|
| |
|
|
|
|
|
|
| |||
| Complement | High | 2 |
|
| ||||
| Medium | 2 |
|
| |||||
| Low | 3 |
|
|
| ||||
| Rare | 10 |
|
|
|
|
|
| |
|
|
|
|
| |||||
| Myosin | High | 4 |
|
|
|
| ||
| Medium | 1 |
| ||||||
| Low | 3 |
|
|
| ||||
| Rare | 7 |
|
|
|
|
|
| |
|
| ||||||||
| Apolipoprotein | High | 2 |
|
| ||||
| Medium | 0 | |||||||
| Low | 2 |
|
| |||||
| Rare | 7 |
|
|
|
|
|
| |
|
| ||||||||
| Heat shock | High | 4 |
|
|
|
| ||
| Medium | 1 |
| ||||||
| Low | 1 |
| ||||||
| Rare | 4 |
|
|
|
| |||
| Protein s100 | High | 4 |
|
|
|
| ||
| Medium | 0 | |||||||
| Low | 0 | |||||||
| Rare | 5 |
|
|
|
|
| ||
| Mucin | High | 1 |
| |||||
| Medium | 0 | |||||||
| Low | 1 |
| ||||||
| Rare | 6 |
|
|
|
|
|
| |
| Annexin | High | 5 |
|
|
|
|
| |
| Medium | 1 |
| ||||||
| Low | 0 | |||||||
| Rare | 2 |
|
| |||||
| 14-3-3 | High | 4 |
|
|
|
| ||
| Medium | 1 |
| ||||||
| Low | 1 |
| ||||||
| Rare | 1 |
| ||||||
| Cystatin | High | 4 |
|
|
|
| ||
| Medium | 1 |
| ||||||
| Low | 1 |
| ||||||
| Rare | 0 | |||||||
| Peroxiredoxin | High | 4 |
|
|
|
| ||
| Medium | 0 | |||||||
| Low | 0 | |||||||
| Rare | 1 |
| ||||||
Gene Ontology (GO) enrichment analysis of selected tear proteins.
| GO ID | GO Term | # of Proteins | |
|---|---|---|---|
|
| |||
| GO:0052548 | Regulation of endopeptidase activity | 42 | 1.43 × 10−22 |
| GO:0006508 | Proteolysis | 79 | 3.50 × 10−20 |
| GO:0006950 | Response to stress | 122 | 6.75 × 10−19 |
| GO:0051336 | Regulation of hydrolase activity | 58 | 6.83 × 10−19 |
| GO:0009605 | Response to external stimulus | 90 | 8.18 × 10−14 |
| GO:0006952 | Defense response | 66 | 1.67 × 10−13 |
| GO:0007010 | Cytoskeleton organization | 59 | 1.96 × 10−13 |
| GO:0042592 | Homeostatic process | 65 | 4.36 × 10−12 |
| GO:0010941 | Regulation of cell death | 61 | 8.42 × 10−12 |
| GO:0098542 | Defense response to other organism | 44 | 1.09 × 10−09 |
| GO:0009617 | Response to bacterium | 35 | 1.21 × 10−09 |
| GO:0006915 | Apoptotic process | 62 | 1.26 × 10−09 |
| GO:0006954 | Inflammatory response | 36 | 2.09 × 10−09 |
| GO:0051050 | Positive regulation of transport | 38 | 4.16 × 10−09 |
| GO:0022610 | Biological adhesion | 51 | 1.20 × 10−08 |
| GO:0006793 | Phosphorus metabolic process | 76 | 1.41 × 10−08 |
|
| |||
| GO:0070062 | Extracellular exosome | 224 | 1.41 × 10−152 |
| GO:1903561 | Extracellular vesicle | 224 | 1.74 × 10−148 |
| GO:0005576 | Extracellular region | 244 | 1.35 × 10−104 |
| GO:0072562 | Blood microparticle | 36 | 4.77 × 10−34 |
| GO:0101002 | Ficolin-1-rich granule | 34 | 1.36 × 10−27 |
| GO:0070161 | Anchoring junction | 55 | 3.09 × 10−21 |
| GO:0005764 | Lysosome | 42 | 1.89 × 10−14 |
| GO:0005773 | Vacuole | 44 | 6.14 × 10−14 |
| GO:0030054 | Cell junction | 70 | 1.84 × 10−11 |
|
| |||
| GO:0061135 | Endopeptidase regulator activity | 31 | 2.56 × 10−23 |
| GO:0061134 | Peptidase regulator activity | 33 | 3.18 × 10−23 |
| GO:0050839 | Cell adhesion molecule binding | 44 | 1.80 × 10−20 |
| GO:0045296 | Cadherin binding | 35 | 4.47 × 10−20 |
| GO:0030234 | Enzyme regulator activity | 63 | 1.35 × 10−18 |
| GO:0008289 | Lipid binding | 36 | 1.77 × 10−09 |
Figure 4Network analyses revealed tear proteins with the highest level of interactions and four canonical pathways enriched in tear proteins. All 329 proteins detected in at least 50% of the samples were analyzed using Ingenuity Pathway Analysis software. (A) Proteins that showed the highest level of protein–protein interactions are depicted by cellular location. A total of four canonical pathways were highly enriched in tear proteins, including acute phase response signaling (B), glucocorticoid receptor signaling (C), LXR/RXR signaling (D), and phagosome formation (E).